Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer.
Seyednasrollah F, Koestler DC, Wang T, Piccolo SR, Vega R, Greiner R, Fuchs C, Gofer E, Kumar L, Wolfinger RD, Kanigel Winner K, Bare C, Neto EC, Yu T, Shen L, Abdallah K, Norman T, Stolovitzky G, Soule HR, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Elo LL, Zhou FL, Guinney J, Costello JC; Prostate Cancer DREAM Challenge Community. Seyednasrollah F, et al. Among authors: sweeney cj. JCO Clin Cancer Inform. 2017 Nov;1:1-15. doi: 10.1200/CCI.17.00018. JCO Clin Cancer Inform. 2017. PMID: 30657384 Free PMC article.
A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.
Resta LP, Pili R, Eisenberger MA, Spitz A, King S, Porter J, Franke A, Boinpally R, Carducci MA, Sweeney CJ. Resta LP, et al. Among authors: sweeney cj. Cancer Chemother Pharmacol. 2011 Feb;67(2):431-8. doi: 10.1007/s00280-010-1328-7. Epub 2010 May 6. Cancer Chemother Pharmacol. 2011. PMID: 20445979 Free PMC article. Clinical Trial.
Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival.
Sharma J, Gray KP, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ. Sharma J, et al. Among authors: sweeney cj. Prostate. 2014 Feb;74(3):225-34. doi: 10.1002/pros.22744. Epub 2013 Oct 16. Prostate. 2014. PMID: 24132762
Preface. Prostate cancer.
Sweeney CJ. Sweeney CJ. Hematol Oncol Clin North Am. 2013 Dec;27(6):xi-xii. doi: 10.1016/j.hoc.2013.10.006. Hematol Oncol Clin North Am. 2013. PMID: 24188263 No abstract available.
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HI. Smith MR, et al. Among authors: sweeney cj. J Clin Oncol. 2014 Oct 20;32(30):3391-9. doi: 10.1200/JCO.2013.54.5954. Epub 2014 Sep 15. J Clin Oncol. 2014. PMID: 25225437 Free PMC article. Clinical Trial.
A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma.
Pal S, Azad A, Bhatia S, Drabkin H, Costello B, Sarantopoulos J, Kanesvaran R, Lauer R, Starodub A, Hauke R, Sweeney CJ, Hahn NM, Sonpavde G, Richey S, Breen T, Kremmidiotis G, Leske A, Doolin E, Bibby DC, Simpson J, Iglesias J, Hutson T. Pal S, et al. Among authors: sweeney cj. Clin Cancer Res. 2015 Aug 1;21(15):3420-7. doi: 10.1158/1078-0432.CCR-14-3370. Epub 2015 Mar 18. Clin Cancer Res. 2015. PMID: 25788492 Free PMC article. Clinical Trial.
274 results